No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter]

Buckley, Adam J. ORCID: https://orcid.org/0000-0001-7471-0273, Tan, Garry D., Gruszka-Goh, Marta, Scanlon, Peter H. ORCID: https://orcid.org/0000-0001-8513-710X, Ansari, Imran and Suliman, Sara G. I. (2025) No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter]. Diabetologia. doi:10.1007/s00125-025-06562-9 (In Press)

Text 15403 Buckley et al (2025) No evidence that tirzepatide can worsen diabetic retinopathy.pdf - Accepted Version Restricted to Repository staff only until 5 October 2026. (Publisher Embargo). Available under License Publisher's Licence. Download (211kB)

Item Type:	Article
Article Type:	Article
Uncontrolled Keywords:	GLP-1 receptor agonist; Glucose-dependent insulinotropic polypeptide; Retinopathy; Tirzepatide; Type 2 diabetes
Subjects:	R Medicine > RE Ophthalmology R Medicine > RM Therapeutics. Pharmacology
Divisions:	Schools and Research Institutes > School of Education, Health and Sciences
Depositing User:	Charlotte Crutchlow
Date Deposited:	22 Oct 2025 09:43
Last Modified:	27 Oct 2025 16:15
URI:	https://eprints.glos.ac.uk/id/eprint/15403

University Staff: Request a correction | Repository Editors: Update this record